News and Updates

Breakthrough T1D is back from Barcelona! The final two days of ATTD were jam-packed with more incredible updates across all areas of our mission. Breakthrough T1D staff chaired and participated in many sessions—including Breakthrough T1D Senior Vice President of Research, Esther Latres, Ph.D.; Vice President of Medical Affairs Anastasia Albanese O’Neill, Ph.D., APRN, CDCES; Senior […]

Greetings from Barcelona, Spain! From March 11–14, 2026, the world’s leading type 1 diabetes (T1D) researchers, healthcare professionals, and industry partners gathered to share groundbreaking advances in T1D science—and Breakthrough T1D–supported work (and staff) were front and center. Below is everything you need to know from the first two days of this remarkable conference, including […]

Our Statement on Deceased Donor Islet Cell Availability & The ISLET Act Curing type 1 diabetes (T1D) is Breakthrough T1D’s number one priority. As the leading global T1D research and advocacy organization, we are currently funding over $450 million in cures research in 23 countries. Everything we do is focused on making cures happen for the T1D […]

Tzield is the first approved disease-modifying therapy for type 1 diabetes, but Breakthrough T1D will make sure it’s not the last.

Learn the basics about autoimmune disease, including prevalence in the U.S., possible causes, and why they are often called "invisible."

One of our most promising avenues toward cures for type 1 diabetes (T1D) is cell therapies. Cell therapies replace destroyed beta cells with functional, insulin-producing cells to restore insulin therapy independence. Right now, there are nearly a dozen cell therapies in clinical testing—and OPF-310 is one of them. OPF-310 cells are derived from porcine (pig) […]

Breakthrough T1D created a guide for sensor issues, from what to do if symptoms and CGM reading do not match to how to get a replacement.

What’s happening? Continuous ketone monitoring (CKM) is on its way. A new paper in The Lancet Diabetes & Endocrinology, titled “International expert recommendations on the application and utility of continuous ketone monitoring for people with diabetes,” was published by Breakthrough T1D and expert collaborators, spearheaded by our Chief Medical Officer, International, Thomas Danne, M.D., Ph.D. […]

Support and resources for issues with continuous glucose monitors (CGMs), including inaccurate readings and faulty sensors.

How quickly a year goes by—and a lot has happened for type 1 diabetes (T1D) in 2025! In these last few weeks leading up to the new year, Breakthrough T1D would like to take a moment to reflect on how far we’ve come in the past 365 days. Read on for the greatest T1D accomplishments […]